Canada’s Drug Pricing Reform Faces Legal Challenge
Executive Summary
Canada’s R&D drug industry says it approached the court as a “necessary step,” given the significant impact of the pricing reforms.
You may also be interested in...
Canadian Court Upholds New Drug Price Comparison Basket – With Caveats
A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.
COVID-19 Causes Further Delay To Canada’s Controversial Pricing Reforms
A delay to implementing drug pricing reforms is an opportunity for Canadian authorities to come up with better proposals, say industry representatives, while authorities remain adamant that action is necessary to lower prices.
Canada To Rethink Controversial Pricing Rules
Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.